Software shall also be deemed to be an active device;
- (5)  'implantable device' means any device, including those that are partially or  wholly absorbed, which is intended:
- -  to be totally introduced into the human body, or
- -  to replace an epithelial surface or  the surface of the eye,
by clinical intervention and which is intended to remain in place after  the procedure.
Any  device  intended  to  be  partially  introduced  into  the  human  body  by  clinical  intervention  and  intended  to remain in place after  the procedure for at least 30 days shall also be deemed to be an implantable device;
- (6)  'invasive  device'  means  any  device  which,  in  whole  or  in  part,  penetrates  inside  the  body,  either  through  a  body orifice  or  through the surface of  the body;
- (7)  'generic  device  group'  means  a  set  of  devices  having  the  same  or  similar  intended  purposes  or  a  commonality  of technology allowing them to be classified in a generic manner not reflecting specific characteristics;
- (8)  'single-use device' means a device that is intended to be used on one individual during a single procedure;
- (9)  'falsified device' means  any  device  with  a  false  presentation of its identity and/or  of its  source  and/or its CE marking certificates or documents relating to CE marking procedures. This definition does not include uninten­ tional non-compliance and is without prejudice to infringements of intellectual property rights;
- (10)  'procedure  pack'  means  a  combination  of  products  packaged  together  and  placed  on  the  market  with  the  purpose of being used for a specific medical purpose;
- (11)  'system'  means  a  combination  of  products,  either  packaged  together  or  not,  which  are  intended  to  be  interconnected or combined to achieve a specific medical purpose;
- (12)  'intended purpose' means  the use for which  a device is intended according to the data supplied by the manufacturer  on  the  label,  in  the  instructions  for  use  or  in  promotional  or  sales  materials  or  statements  and  as specified by the manufacturer in the clinical evaluation;
- (13)  'label'  means  the  written,  printed  or  graphic  information  appearing  either  on  the  device  itself,  or  on  the  packaging of each unit or on the packaging of multiple devices;
- (14)  'instructions for  use'  means the information provided by the manufacturer  to inform the user of a device's intended purpose and proper use and of any precautions to be taken;
- (15) 'Unique  Device  Identifier'  ('UDI')  means  a  series  of  numeric  or  alphanumeric  characters  that  is  created  through  in­ ternationally  accepted  device  identification  and  coding  standards  and  that  allows  unambiguous  identification  of specific devices on the market; - (16)  'non-viable' means having no potential for metabolism or multiplication;
- (17)  'derivative' means a 'non-cellular substance' extracted from human or animal tissue or cells through a manufacturing process. The final substance used for manufacturing of the device in this case does not contain any cells or  tissues;
- (18)  'nanomaterial'  means  a  natural,  incidental  or  manufactured  material  containing  particles  in  an  unbound  state  or  as an  aggregate  or  as  an  agglomerate  and  where,  for  50  %  or  more  of  the  particles  in  the  number  size  distribution, one or more external dimensions is in the size range 1-100 nm;
- Fullerenes,  graphene  flakes  and  single-wall  carbon  nanotubes  with  one  or  more  external  dimensions  below  1  nm shall also be deemed to be nanomaterials;
- (19)  'particle',  for  the  purposes  of  the  definition  of  nanomaterial  in  point  (18),  means  a  minute  piece  of  matter  with defined physical boundaries;
- (20)  'agglomerate', for  the  purposes of  the definition of nanomaterial in point (18), means a collection of weakly bound particles  or  aggregates  where  the  resulting  external  surface  area  is  similar  to  the  sum  of  the  surface  areas  of  the individual components;
- (21)  'aggregate',  for  the  purposes  of  the  definition  of  nanomaterial  in  point  (18),  means  a  particle  comprising  of strongly bound or fused particles;
- (22)  'performance' means the ability of a device to achieve its intended purpose as stated by the manufacturer;
- (23)  'risk'  means the combination of the probability of occurrence of harm and the severity of that harm;
- (24)  'benefit-risk  determination'  means  the  analysis  of  all  assessments  of  benefit  and  risk  of  possible  relevance  for  the use  of  the  device  for  the  intended  purpose,  when  used  in  accordance  with  the  intended  purpose  given  by  the manufacturer;
- (25)  'compatibility'  is  the  ability  of  a  device,  including  software,  when  used  together  with  one  or  more  other  devices  in accordance with its intended purpose, to:
- (a)   perform without losing or compromising the ability to perform as intended, and/or
- (b)   integrate  and/or  operate  without  the  need  for  modification  or  adaption  of  any  part  of  the  combined  devices, and/or
- (c)   be  used together  without conflict/interference or adverse reaction.
- (26)  'interoperability'  is  the  ability  of  two  or  more  devices,  including  software,  from  the  same  manufacturer  or  from different manufacturers, to:
- (a)   exchange information and use the information that has been exchanged for  the correct execution of a specified function without changing the content of the data, and/or
- (b)   communicate with each other, and/or
- (c)   work together as intended.
- (27)  'making available on  the market' means  any  supply  of  a device, other than an investigational device, for distribution, consumption or use on the Union market in the course of a commercial activity, whether in return for payment or free of charge;
- (28)  'placing  on  the  market'  means  the  first  making  available  of  a  device,  other  than  an  investigational  device,  on  the Union market;
- (29)  'putting  into  service'  means  the  stage  at  which  a  device,  other  than  an  investigational  device,  has  been  made available to the final user as being ready for use on the Union market for  the first time for its intended purpose;
- (30)  'manufacturer'  means  a  natural  or  legal  person  who  manufactures  or  fully  refurbishes  a  device  or  has  a  device designed, manufactured or fully refurbished, and markets that device under its name or  trademark;
- (31)  'fully  refurbishing',  for  the  purposes  of  the  definition  of  manufacturer,  means  the  complete  rebuilding  of  a  device already placed on the market or put into service, or  the making of a new device from used devices, to bring it into conformity with this Regulation, combined with the assignment of a new lifetime to the refurbished device; - (32)  'authorised  representative'  means  any  natural  or  legal  person  established  within  the  Union  who  has  received  and accepted a written mandate from a manufacturer, located outside the Union, to act on the manufacturer's behalf in relation to specified tasks with regard to the latter's obligations under  this Regulation;
- (33)  'importer' means any natural or legal person established within the Union that places a device from a third country on the Union market;
- (34)  'distributor'  means  any  natural  or  legal  person  in  the  supply  chain,  other  than  the  manufacturer  or  the  importer, that makes a device available on the market, up until the point of putting into service;
- (35)  'economic  operator'  means  a  manufacturer,  an  authorised  representative,  an  importer,  a  distributor  or  the  person referred to in Article 22(1) and 22(3);
- (36)  'health  institution'  means  an  organisation  the  primary  purpose  of  which is  the  care  or  treatment  of  patients  or  the promotion of public health;
- (37)  'user' means any healthcare professional or lay person who uses a device;
- (38)  'lay  person'  means  an  individual  who  does  not  have  formal  education  in  a  relevant  field  of  healthcare  or  medical discipline;
- (39)  'reprocessing'  means  a  process  carried  out  on  a  used  device  in  order  to  allow  its  safe  reuse  including  cleaning, disinfection,  sterilisation  and  related  procedures,  as  well  as  testing  and  restoring  the  technical  and  functional  safety of  the used device;
- (40)  'conformity  assessment'  means  the  process  demonstrating  whether  the  requirements  of  this  Regulation  relating  to a device have been fulfilled;
- (41)  'conformity  assessment  body'  means  a  body  that  performs  third-party  conformity  assessment  activities  including calibration, testing, certification and inspection;
- (42)  'notified body' means a conformity assessment body designated in accordance with this Regulation;
- (43)  'CE  marking of conformity' or 'CE marking' means a marking by which a manufacturer indicates that a device is in conformity  with  the  applicable  requirements  set  out  in  this  Regulation  and  other  applicable  Union  harmonisation legislation providing for its affixing;
- (44)  'clinical  evaluation'  means  a  systematic  and  planned  process  to  continuously  generate,  collect,  analyse  and  assess the  clinical  data  pertaining  to  a  device  in  order  to  verify  the  safety  and  performance,  including  clinical  benefits,  of the device when used as intended by the manufacturer;
- (45)  'clinical  investigation'  means  any  systematic  investigation  involving  one  or  more  human  subjects,  undertaken  to assess the safety or  performance of a device;
- (46)  'investigational device' means a device that is assessed in a clinical investigation;
- (47)  'clinical investigation plan' means  a  document  that  describes  the  rationale, objectives,  design,  methodology, monitoring, statistical considerations, organisation and conduct of a clinical investigation;
- (48)  'clinical data' means information concerning safety or performance that is generated from the use of a device and is sourced from the following:
- -  clinical investigation(s) of the device concerned,
- -  clinical  investigation(s)  or  other  studies  reported in  scientific  literature,  of a  device  for  which  equivalence  to  the device in question can be demonstrated,
- -  reports  published  in  peer  reviewed  scientific  literature  on  other  clinical  experience  of  either  the  device  in question or a device for  which equivalence to the device in question can be demonstrated,
- -  clinically  relevant  information  coming  from  post-market  surveillance,  in  particular  the  post-market  clinical follow-up;
- (49)  'sponsor'  means  any  individual,  company,  institution  or  organisation  which  takes  responsibility  for  the  initiation, for  the management and setting up of the financing of the clinical investigation;
- (50)  'subject'  means an individual who participates in a clinical investigation; - (51)  'clinical  evidence'  means  clinical  data  and  clinical  evaluation  results  pertaining  to  a  device  of  a  sufficient  amount and  quality  to  allow  a  qualified  assessment  of  whether  the  device  is  safe  and  achieves  the  intended  clinical benefit(s),  when used as intended by the manufacturer;
- (52)  'clinical  performance'  means the ability of a device, resulting from any direct or  indirect medical effects which stem from  its  technical  or  functional  characteristics,  including  diagnostic  characteristics,  to  achieve  its  intended  purpose as  claimed  by  the  manufacturer,  thereby  leading  to  a  clinical  benefit  for  patients,  when  used  as  intended  by  the manufacturer;
- (53)  'clinical  benefit'  means  the  positive  impact  of  a  device  on  the  health  of  an  individual,  expressed  in  terms  of a  meaningful, measurable, patient-relevant clinical outcome(s), including outcome(s)  related to diagnosis, or a positive impact on patient management or public health;
- (54)  'investigator'  means  an  individual  responsible  for  the  conduct  of  a  clinical  investigation  at  a  clinical  investigation site;
- (55)  'informed  consent'  means  a  subject's  free  and  voluntary  expression  of  his  or  her  willingness  to  participate  in a  particular  clinical  investigation,  after  having  been  informed  of  all  aspects  of  the  clinical  investigation  that  are relevant  to  the  subject's  decision  to  participate  or,  in  the  case  of  minors  and  of  incapacitated  subjects,  an  authoris­ ation or agreement from their legally designated representative to include them in the clinical investigation;
- (56)  'ethics  committee'  means  an  independent  body  established  in  a  Member  State  in  accordance  with  the  law  of  that Member State  and  empowered  to give  opinions  for  the  purposes  of  this  Regulation,  taking  into  account  the  views of  laypersons, in particular  patients or  patients' organisations;
- (57)  'adverse  event'  means  any  untoward  medical  occurrence,  unintended  disease  or  injury  or  any  untoward  clinical signs,  including  an  abnormal  laboratory  finding,  in  subjects,  users  or  other  persons,  in  the  context  of  a  clinical investigation, whether or not related to the investigational device;
- (58)  'serious adverse event' means any adverse event that led to any of the following:
- (a)   death,
- (b)   serious deterioration in the health of the subject, that resulted in any of  the following:
- (i) life-threatening illness or  injury,
- (ii)   permanent impairment of a body structure or a body function,
- (iii)   hospitalisation or  prolongation of patient hospitalisation,
- (iv)   medical  or  surgical  intervention  to  prevent  life-threatening  illness  or  injury  or  permanent  impairment  to a body structure or a body function,
- (v) chronic disease,
- (c)   foetal distress, foetal death or a congenital physical or  mental impairment or birth defect;
- (59)  'device  deficiency'  means  any  inadequacy  in  the  identity,  quality,  durability,  reliability,  safety  or  performance  of an investigational device, including malfunction, use errors or inadequacy in information supplied by the manufacturer;
- (60)  'post-market  surveillance'  means  all  activities  carried  out  by  manufacturers  in  cooperation  with  other  economic operators  to  institute  and  keep  up  to  date  a  systematic  procedure  to  proactively  collect  and  review  experience gained from devices they place on the market, make available on the market or  put into service for  the purpose of identifying any need to immediately apply any necessary corrective or preventive actions;
- (61)  'market  surveillance'  means  the  activities  carried  out  and  measures  taken  by  competent  authorities  to  check  and ensure  that  devices  comply  with  the  requirements  set  out  in  the  relevant  Union  harmonisation  legislation  and  do not endanger health, safety or any other aspect of public interest protection;
- (62)  'recall'  means  any  measure  aimed  at  achieving  the  return  of  a  device  that  has  already  been  made  available  to  the end user;
- (63)  'withdrawal'  means  any  measure  aimed  at  preventing  a  device  in  the  supply  chain  from  being  further  made available on the market;
- (64)  'incident'  means  any  malfunction  or  deterioration  in  the  characteristics  or  performance  of  a  device  made  available on  the  market,  including  use-error  due  to  ergonomic  features,  as  well  as  any  inadequacy  in  the  information supplied by the manufacturer and any undesirable side-effect;
- (65)  'serious  incident'  means  any  incident  that  directly  or  indirectly  led,  might  have  led  or  might  lead  to  any  of  the following:
- (a)   the  death of a patient, user or other  person,
- (b)   the  temporary or  permanent serious deterioration of a patient's, user's or other  person's state of health,
- (c)   a  serious public health threat;
- (66)  'serious  public  health  threat'  means  an  event  which  could  result  in  imminent  risk of  death,  serious  deterioration  in a  person's  state  of  health,  or  serious  illness,  that  may  require  prompt  remedial  action,  and  that  may  cause significant morbidity or mortality in humans, or  that is unusual or unexpected for the given place and time;
- (67)  'corrective  action'  means  action  taken  to  eliminate  the  cause  of  a  potential  or  actual  non-conformity  or  other undesirable situation;
- (68)  'field  safety  corrective  action'  means  corrective  action  taken  by  a  manufacturer  for  technical  or  medical  reasons  to prevent or reduce the risk of a serious incident in relation to a device made available on the market;
- (69)  'field  safety  notice'  means  a  communication  sent  by  a  manufacturer  to  users  or  customers  in  relation  to  a  field safety corrective action;
- (70)  'harmonised standard' means a European standard as defined in point (1)(c) of Article 2 of Regulation (EU) No 1025/2012;
- (71)  'common  specifications'  (CS)  means  a  set  of  technical  and/or  clinical  requirements,  other  than  a  standard,  that provides a means of complying with the legal obligations applicable to a device, process or system.
## Article 3
## Amendment of certain definitions
The Commission is empowered to adopt delegated acts in accordance with Article 115 in order  to amend the definition of  nanomaterial  set  out  in  point  (18)  and  the  related  definitions  in  points  (19),  (20)  and  (21)  of  Article  2  in  the  light  of technical and scientific progress and taking into account definitions agreed at Union and international level.
## Article 4
## Regulatory status of products
- 1. Without  prejudice  to  Article  2(2)  of  Directive  2001/83/EC,  upon  a  duly  substantiated  request  of  a  Member  State, the  Commission  shall,  after  consulting  the  Medical  Device  Coordination  Group  established  under  Article  103  of  this Regulation ('MDCG'), by means of implementing acts, determine whether or not a specific product, or category or group of  products,  falls  within  the  definitions  of  'medical  device'  or  'accessory  for  a  medical  device'.  Those  implementing  acts shall be adopted in accordance with the examination procedure referred to in Article 114(3) of this Regulation.
- 2. 